Yttrium-90 SIRT in NET

Sander C. Ebbers*, Arthur J.A.T. Braat, Marnix G.E.H. Lam

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

During the past two decades, selective internal radiotherapy (SIRT, i.e., radioembolization) is being increasingly applied in patients suffering from unresectable hepatic metastases of neuroendocrine tumors (NET). Essentially, SIRT consists of administering microscopic spheres into the arterial vasculature of the liver. The treatment is increasingly used in patients liver-dominant disease, and can result in prolongation of survival while retaining quality of life. Current research mainly focusses on improved patient selection and optimization of dosimetry, thereby reducing healthy liver tissue damage and increasing tumor response.

Original languageEnglish
Title of host publicationLiver Intra-arterial PRRT with 111In-Octreotide
Subtitle of host publicationThe Tumoricidal Efficacy of 111In Auger Electron Emission
PublisherSpringer International Publishing
Pages231-239
Number of pages9
ISBN (Electronic)9783030707736
ISBN (Print)9783030707729
DOIs
Publication statusPublished - 30 May 2021

Fingerprint

Dive into the research topics of 'Yttrium-90 SIRT in NET'. Together they form a unique fingerprint.

Cite this